The results of in vivo biodistribution showed that the tumor fluorescence intensity of the DPC@ICD-Gd-Tic group was much stronger than that of the non-targeted DP@ICD-Gd-Tic group, indicating that the modification of CREKA could mediate specific recognition of fibrin-fibronectin complexes in microthrombi to improve efficient drug delivery at tumor sites, whereas DP@ICD-Gd-Tic without CREKA peptide modification relies only on tumor EPR effect. The gene discussed is FN1; the disease is neoplasm.